No abstract

Introduction: In order to change the long-term economic development model which is at the expense of the environment, China proposed a series of new energy development and environmental intervention policies. However, there is no evidence to support the impact of urban development on the green development efficiency (GDE) under China’s macroeconomic policies at present. In order to answer this research question and help the government to improve the GDE, this study takes the Yangtze River Economic Belt (YREB) city cluster (41 cities) in China as an example to conduct an empirical study.Methods: We first measure the GDE of these cities by Slack Based Model (SBM). Then, the Tobit model is used to measure the impact of urban development elements, namely population urbanization, land urbanization, and urban industrial development, on GDE.Results and Discussion: The analysis of the data leads to the following conclusions and suggestions: 1) The GDE of the city cluster in the YREB has generally been improved driven by policies. But compared to policy interventions, the level of science, technology and management are the primary drivers of long-term improvement in GDE. 2) In order to avoid the economic development and environmental capacity failure to afford the increase in energy consumption and pollution discharge caused by population urbanization and land urbanization, local governments need to promote energy transformation, increase environmental protection efforts and attract top-tier talent. 3) The improvement of GDE by industrial upgrading is a dynamic and slow process, and blindly pushing industrial restructuring will lead to a decline in GDE. Therefore, the Chinese government needs to provide an ecologically suitable environment for local industrial development, which needs to avoid “pulling out the seedlings” and “one-size-fits-all” approach.

No abstract

Background Migraine is a worldwide epidemic neurological disorder that has a significant influence on the quality of life. Migraine attacks are considered to be related to a calcitonin gene‐related peptide (CGRP) signaling molecule, and anti‐CGRP medications are used to abort and prevent migraine attacks. Erenumab, a monoclonal antibody that targets the CGRP receptor, is the first migraine preventive medication approved by the US Food and Drug Administration. In the present study, we evaluate the efficacy and safety of erenumab. Objective This study aims to systematically assess the efficacy and safety of erenumab as a migraine preventive treatment compared to a placebo. Methods Randomized, placebo‐controlled, single or double‐blind trials were searched through MEDLINE, Embase, Cochrane Library, and http://clinicaltrials.gov up to May 2022. The efficacy outcomes we collected include changes from baseline on monthly migraine days, monthly acute migraine‐specific medication days, ≥50% responder rate, ≥75% responder rate, and 100% responder rate at week 12. Safety outcomes include treatment emergent adverse events, serious adverse events, and any adverse event that leads to discontinuation of treatment. The study was registered with PROSPERO (Registry number: CRD42022338861). Result In all eight included trials, we found that erenumab (28, 70, and 140 mg) is very effective and has a significantly greater reduction in baseline monthly migraine days (28 mg: mean difference [MD] = −1.1, 95% confidence interval [CI]: −2.0 to −0.2, p = 0.020; 70 mg: MD = −1.4, 95% CI: −1.8 to −1.1, p < 0.001, I2 = 26%; 140 mg: MD = −1.8, 95% CI: −2.1 to −1.4, p < 0.001, I2 = 0%) than placebo at week 12, especially with 140 mg. Otherwise, we found that there were no statistical differences in the occurrence of adverse events (7 mg: risk ratio [RR] = 0.9, 95% CI: 0.7 to 1.2, p = 0.570; 21 mg: RR = 1.0, 95% CI: 0.8 to 1.2, p = 0.730; 28 mg: RR = 0.9, 95% CI: 0.7 to 1.1, p = 0.340; 70 mg: RR = 1.0, 95% CI: 0.9 to 1.0, p = 0.230, I2 = 0%; 140 mg: RR = 1.0, 95% CI: 0.9 to 1.1, p = 0.880, I2 = 40%) between the erenumab and placebo groups. Conclusions In our study, we found that erenumab, especially at the dose of 140 mg, is an effective and well‐tolerated preventive treatment for migraine.